Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms JUVE-BASIS
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
- 13 Jul 2023 Results assessing safety and efficacy Baricitinib , published in the Lancet
- 14 Nov 2022 Results assessing baricitinib efficacy and safety in pediatric patients with juvenile idiopathic arthritis and an inadequate response to cs or b-DMARDs presented at the ACR Convergence 2022.
- 04 Jun 2022 Primary endpoint has been met (Time to Disease Flare) , according to Results presented at the 23rd Annual Congress of the European League Against Rheumatism